Based on a Tumor Immunology Symposium held in Pittsburgh, this work provides comprehensive coverage of the most important aspects of tumor immunology. It reveals novel approaches to the immunotherapy of cancer and presents complex issues in an accessible manner.
Part I. Introduction. Tumor-Associated Antigens and the Role of Antibodies and Cellular Immunity in Cancer. The Immunogenicity of Foreign Monoclonal Antibodies in Human Disease Applications: Problems and Current Approaches. Additive and Synergistic Interactions of Monoclonal Antibodies and Immunotoxins Reactive with Breast and Ovarian Cancer. Tumor Rejection Antigens of the Chemically Induced BALB/5 Meth A Sarcoma. Part II. Introduction. Antitumor Effector Cells: Characteristics and Basic Mechanisms. Phenotypic and Functional Characteristics of Human A-NK Cells. Regulation and Function of Fibronectin Receptors Expressed by Natural Killer Cells. Growth Requirements, Binding and Migration of Human Natural Killer Cells. Regulation of Monocytes by IL-2-Activated Killer Cells. Identification and Enrichment of Proteolytic Enzymes of IL-2 Activated Rat Natural Killer (A-NK) Cells: Potential Physiological Roles in NK Cell Function. Part III. Introduction. Animal Models in Tumor Biology. Effects of rhIL-7 on Leukocyte Subsets in Mice: Implications for Antitumor Activity. Up-Regulation of Tumor Cell Sensitivity to Natural Cell-Mediated Cytotoxicity by UV Light Irradiation. Studies on NK Cell Precursors in Mice. Part IV. Introduction. Tumor Microenvironment and Immune Effector Cells. Tumor-Infiltrating Lymphocytes in Human Solid Tumors. Localization of Immune Effector Cells to Tumor Metastases. Anti-tumor Effector Cells: Extravasation and Control of Metastasis I Tumor Microenvironment and Immune Effector Cells: Isolation, Large Scale Propagation and Characterization of CD8+ Tumor Infiltrating Lymphocytes from Renal Cell Carcinomas. Part V. Introduction. Immunomodulation and Antitumor Mechanisms. Interleukin-Induced Tumor Immunogenicity. Biological Significance of Autologous Tumor Killing. Biological Response Modifiers and Chemotherapeutic Agents that After Interleukin 2 Activities. Part VI. Introduction. Immunotherapy of Tumors. New Perspectives in Immunotherapy of Leukemia. T